Compare ARK Genomic Revolution ETF (ARKG) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs VF Corp — how do they compare? ARK Genomic Revolution ETF trades at $44.29, while VF Corp trades at $14.78 (market cap $5.86B). The key difference: VF Corp pays a 2.42% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, VF Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | VFC | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $21.55 |
52-Week Low | $24.02 | $12.21 |
Market Cap | — | $5.86B |
Enterprise Value | — | $10.14B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
VFC trades at $14.99, up 1.63% on the day, with a bearish technical signal and mixed earnings. Recent Q1 2027 results missed EPS estimates, though revenue exceeded expectations. The company faces challenges with Vans brand performance and a CFO transition, but maintains a raised fiscal 2027 sales outlook. Cash flow trends show improvement in 2026, with net cash flow turning positive.
Outlook remains cautious due to weak consumer sentiment and brand-specific headwinds, but deleveraging progress and margin gains offer potential upside. Risks include persistent Vans drag and macro pressures. Analyst consensus is Hold with a $17.44 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
